^
    Back
    Association details:
    Biomarker:MET exon 14 mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    ASCO 2021
    Title:

    Immunotherapy in patients with lung cancer with driver mutations: A single center experience.

    Published date:
    05/19/2021
    Excerpt:
    We found MET exon 14 skip mutation in 2...Single agent checkpoint inhibitors seem to have a limited impact in treatment in patients with driver mutations....We do see benefit in patients who received PD1/PDL1 inhibitors in combination with chemotherapy with/ without Bevacizumab.
    Secondary therapy:
    carboplatin + paclitaxel
    DOI:
    10.1200/JCO.2021.39.15_suppl.e21170
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Lung Cancer
    Title:

    Durable responses to immunotherapy of non-small cell lung cancers harboring MET exon-14-skipping mutation: A series of 6 cases

    Published date:
    10/16/2020
    Excerpt:
    Among 25 patients with METex14-mutated NSCLCs, 13 of whom were ICI-treated, 6 had prolonged responses: 5 women, 1 man; 57-80 years old; 3 never-smokers, 1 ex-smoker and 2 smokers; 5 adenocarcinomas, 1 sarcomatoid carcinoma; 5 received nivolumab, 1 pembrolizumab.
    DOI:
    10.1016/j.lungcan.2020.09.008